Serotonin Receptor Agonists: all 773 studies that test it

Page 5 of 8. Open to participants first (148), then studies with results posted, then the rest; newest registration first within each.

• Psilocybin in Functional Neurological DisorderCompletedNCT05723276Not applicable
• Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDActive, not recruitingNCT05711940Phase 3
• Does Psilocybin Require Psychedelic Effects to Treat Depression?CompletedNCT05710237Phase 2
• Neural and Physiological Correlates of Psychedelic Sub-statesActive, not recruitingNCT05698511Phase 1
• Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy VolunteersCompletedNCT05698095Phase 1
• Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)CompletedNCT05695495Phase 1
• Psilocybin for Major Depressive DisorderWithdrawnNCT05675800Phase 2
• A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy VolunteersCompletedNCT05674669Phase 1
• The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship QualityStatus unknownNCT05670184Phase 1/2
• Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and CapsaicinCompletedNCT05654298Not applicable
• Psilocybin in Adults With and Without Autism Spectrum DisorderCompletedNCT05651126Not applicable
• Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)Active, not recruitingNCT05646303Phase 2
• IM and IV SPL026 Drug Product in Healthy ParticipantsCompletedNCT05644093Phase 1
• Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic EncephalopathyCompletedNCT05626634Phase 2
• Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDCompletedNCT05624268Phase 3
• PET Synaptogenesis After Psilocybin In DEpression RecoveryWithdrawnNCT05601648Phase 2
• Effect of SSRIs on Response to Psilocybin TherapyWithdrawnNCT05594667Phase 2
• Clinical Study of DMT in Healthy AdultsCompletedNCT05573568Phase 1
• Safety and Tolerability of Psilocybin in Post-Traumatic Stress DisorderWithdrawnNCT05562973Phase 1
• Single and Repeat Doses of DMT in Healthy SubjectsActive, not recruitingNCT05559931Phase 1
• PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related BurnoutCompletedNCT05557643Phase 1
• Psilocybin for the Treatment of Veterans With Post-Traumatic Stress DisorderCompletedNCT05554094Phase 2
• SPL026 With or Without SSRIs in Participants With MDDCompletedNCT05553691Phase 1
• Effects of Psilocybin in Obsessive Compulsive DisorderActive, not recruitingNCT05546658Early Phase 1
• Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic PainCompletedNCT05506982Phase 1
• The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit PatientsCompletedNCT05496179Phase 1/2
• Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyCompletedNCT05481736Phase 2
• An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's PharmacokineticsCompletedNCT05478278Phase 1
• Bioavailability Study of Psilocybin in Normal AdultsWithdrawnNCT05467761Phase 1
• Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by VertigoCompletedNCT05430217Phase 3
• Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use DisorderActive, not recruitingNCT05421065Phase 2
• Psilocybin-assisted Therapy for Treatment of Alcohol Use DisorderCompletedNCT05416229Phase 2
• Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality DisorderCompletedNCT05399498Phase 2
• Acute Dose-dependent Effects of DMT in Healthy SubjectsCompletedNCT05384678Phase 1
• The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDDWithdrawnNCT05381974Phase 2
• Preventing Gastric Glitch With Prucalopride and Buspirone: N-of-1 Clinical TrialCompletedNCT05377619Phase 1/2
• Effects of Repeated Psilocybin Dosing in OCDActive, not recruitingNCT05370911Phase 1
• Study to Investigate LP352 in Subjects With Developmental and Epileptic EncephalopathiesCompletedNCT05364021Phase 1/2
• Serotonin-receptor Agonism in Reward ProcessingCompletedNCT05357547Phase 2
• Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use DisorderTerminatedNCT05322954Phase 1
• Comparing the Effects of Psilocin and Psilocybin in Healthy AdultsActive, not recruitingNCT05317689Phase 1
• Effects of Psilocybin in Post-Treatment Lyme DiseaseCompletedNCT05305105Phase 1
• Mood and Cognitive Effects of Psilocybin in Healthy ParticipantsWithdrawnNCT05252598Early Phase 1
• Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress DisorderActive, not recruitingNCT05243329Phase 2
• Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid UseWithdrawnNCT05242029Phase 2
• Exploratory Study of Low Dose PsilocybinWithdrawnNCT05227742Early Phase 1
• Psilocybin-assisted Therapy for Phantom Limb PainActive, not recruitingNCT05224336Phase 1
• The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationCompletedNCT05220410Phase 2
• Prucalopride and Cognition in Recovered DepressionCompletedNCT05220228Not applicable
• Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal CancersCompletedNCT05220046Phase 1
• Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of MigraineTerminatedNCT05214001Phase 4
• Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With MigraineCompletedNCT05211050Not applicable
• Εffectiveness of Intrauterine Antibiotic Administration for Treatment of Chronic EndometritisStatus unknownNCT05205993Phase 2
• Effects of LSD on Neuroplasticity in Healthy SubjectsCompletedNCT05177419Phase 1
• Pharmacokinetics of GH001 in Healthy VolunteersCompletedNCT05163691Phase 1
• Naturalistic Study of Microdosing With PsilocybinCompletedNCT05160220Not applicable
• Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture HeadacheCompletedNCT05108688Phase 4
• Psilocybin Therapy for Depression in Bipolar II DisorderActive, not recruitingNCT05065294Phase 2
• Single Ascending Dose Study With 5-MeO-DMT in Healthy SubjectsCompletedNCT05032833Phase 1
• Psilocybin for Treatment-Resistant DepressionCompletedNCT05029466Phase 2
• Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical CystectomyStatus unknownNCT05001763Phase 2
• Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel SyndromeStatus unknownNCT04985669Phase 4
• Psilocybin-Enhanced Psychotherapy for Methamphetamine Use DisorderActive, not recruitingNCT04982796Phase 1/2
• Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine AttacksStatus unknownNCT04948164Phase 3
• Efficacy of Mosapride on Recovery of Intestinal Motility After Elective Colorectal Cancer SurgeryStatus unknownNCT04905147Not applicable
• Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)TerminatedNCT04905121Phase 1
• LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy SubjectsCompletedNCT04865653Phase 1
• Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of ConsciousnessCompletedNCT04849013Phase 1
• Pilot RECAP Study in Healthy VolunteersCompletedNCT04842045Phase 1
• The Effects of Prucalopride in Patients With Constipation Predominant Irritable Bowel SyndromeStatus unknownNCT04757493Phase 2/3
• PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)Active, not recruitingNCT04754061Phase 1/2
• Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility StudyActive, not recruitingNCT04718792Phase 2
• Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy SubjectsCompletedNCT04716335Early Phase 1
• Clinical Study of GH001 in DepressionCompletedNCT04698603Phase 1/2
• Sumatriptan and GlucoseStatus unknownNCT04690270Early Phase 1
• SPL026 (DMT Fumarate) in Healthy Subjects and MDD PatientsCompletedNCT04673383Phase 1/2
• Efficacy and Safety of Psilocybin in Treatment-Resistant Major DepressionCompletedNCT04670081Phase 2
• Evaluation of Psilocybin in Anorexia Nervosa: Safety and EfficacyCompletedNCT04661514Phase 2
• Safety of GH001 in Healthy VolunteersCompletedNCT04640831Phase 1
• The Effect of Psilocybin on MDD Symptom Severity and Synaptic DensityCompletedNCT04630964Phase 2
• Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderActive, not recruitingNCT04620759Phase 2
• The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive DisorderStatus unknownNCT04593563Phase 2
• Study of Psilocybin Enhanced Group Psychotherapy in Patients With CancerCompletedNCT04522804Early Phase 1
• Effects of MDMA Co-administration on the Response to LSD in Healthy SubjectsCompletedNCT04516902Phase 1
• Psilocybin as a Treatment for Anorexia Nervosa: A Pilot StudyCompletedNCT04505189Phase 1/2
• Precision Functional Brain Mapping in PsilocybinCompletedNCT04501653Early Phase 1
• Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic GastrectomyCompletedNCT04493125Not applicable
• Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord InjuryActive, not recruitingNCT04458324Phase 2
• An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)Active, not recruitingNCT04433858Phase 2
• The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.Status unknownNCT04433845Phase 2
• The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric SensitivityCompletedNCT04429802Not applicable
• A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 YearsCompletedNCT04421105Phase 1
• Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of MigraineCompletedNCT04384367Phase 3
• Effects of Dimethyltryptamine in Healthy SubjectsCompletedNCT04353024Phase 1
• Effects of Serotonin Agonist Buspirone on Multimodal Esophageal Stimulation in Healthy VolunteersCompletedNCT04352686Not applicable
• The Comparative Analysis Between Motilitone and Gasmotin for the Symptom Relief in Gallstone Patients With Functional DyspepsiaStatus unknownNCT04350346Not applicable
• Prophylactic Effects of Psilocybin on Chronic Cluster HeadacheTerminatedNCT04280055Phase 1/2
• Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).Status unknownNCT04260711Not applicable
• Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture HeadacheCompletedNCT04257851Phase 4
• Comparative Acute Effects of LSD, Psilocybin and MescalineCompletedNCT04227756Phase 1

← Serotonin Receptor Agonists overview